Prospective evaluation of whole-body diffusion-weighted MRI for staging patients with gastroenteropancreatic neuroendocrine tumors

Prospective evaluation of whole-body diffusion-weighted MRI for staging patients with gastroenteropancreatic neuroendocrine tumors - GEP-NET

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036050

Enrollment

180

Registered

2025-05-06

Start date

2025-07-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant gastroenteropancreatic neuroendocrine tumor (GEP-NET)

Interventions

Group 1: Single-arm, prospective observational study in patients with histologically confirmed GEP-NET undergoing clinically indicated SSTR-PET/CT and liver MRI. In addition, whole-body diffusion-weig

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Age: =18 years - Histologically confirmed GEP-NET - Indication for an SSTR-PET/CT and a liver MRI with hepatocyte-specific contrast agent - Life expectancy of at least 6 months

Exclusion criteria

Exclusion criteria: - Contraindication to PET/CT - Contraindication to MRI - Known pregnancy

Design outcomes

Primary

Measure	Time frame
Detection rate of existing liver lesions	—

Secondary

Measure	Time frame
• Detection rate of existing extrahepatic lesions depending on the organ system • Sensitivity, specificity, positive and negative predictive value of patient-related hepatic and extrahepatic lesions • Overall Survival (OS) • Progression-Free Survival (PFS) • Body Mass Index (weight and height) • Body composition (total body, subcutaneous, visceral, intermuscular, and total fat tissue) • Hemoglobin • Erythrocytes • C-reactive protein • Chromogranin A • Neuron-specific enolase • Ki-67 • Neutrophil-to-lymphocyte ratio • Alkaline phosphatase • Glutamate oxaloacetate transaminase • Urea • Lactate dehydrogenase	—

Measure

Time frame

• Detection rate of existing extrahepatic lesions depending on the organ system • Sensitivity, specificity, positive and negative predictive value of patient-related hepatic and extrahepatic lesions • Overall Survival (OS) • Progression-Free Survival (PFS) • Body Mass Index (weight and height) • Body composition (total body, subcutaneous, visceral, intermuscular, and total fat tissue) • Hemoglobin • Erythrocytes • C-reactive protein • Chromogranin A • Neuron-specific enolase • Ki-67 • Neutrophil-to-lymphocyte ratio • Alkaline phosphatase • Glutamate oxaloacetate transaminase • Urea • Lactate dehydrogenase

—

Countries

Germany

Contacts

Public ContactClemens Cyran

Klinikum der Universität München, Klinik und Poliklinik für Radiologie

Clemens.Cyran@med.uni-muenchen.de089 4400 73620

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026